ICIs were developed against programmed cell death ligand 1 (PD-L1) on cancer cells, and the immune suppressive receptors programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) on cytotoxic T cells (1). The gene discussed is PDCD1; the disease is cancer.